Indus Biotech Limited
Indus Biotech Limited is a Public Non-govt company company incorporated in 1995 and based in Maharashtra, India. Indus Biotech Limited operates in Chemical substances used in the manufacture of anti-biotic, manufacturing (NIC 24231) with authorized capital of ₹43.00 Cr and paid-up capital of ₹31.04 Cr. For 2023-24, the company reported revenue of ₹62.83 Cr and profit after tax of ₹7.41 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 67/100 (grade C), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
INDUS BIOTECH LIMITED is the legal entity of Indus Biotech.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +23d | filed |
| MGT-7 | FY2023-24 | 20 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +16d | filed |
| MGT-7 | FY2022-23 | 23 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Indus Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 100546518 | Axis Bank Ltd(Bank) | ₹20.71 Cr | 19 Sep 2022 | Satisfied |
| 892357531 | State Bank of India(Bank) | ₹2.36 Cr | 27 Jan 2019 | Open |
| 143365463 | HDFC Bank Ltd(Bank) | ₹15.73 Cr | 12 Mar 2020 | Open |
| 455186068 | ICICI Bank Ltd(Bank) | ₹18.48 Cr | 12 Mar 2021 | Satisfied |
| 902659294 | Axis Bank Ltd(Bank) | ₹2.88 Cr | 19 Sep 2021 | Open |
| 821296844 | ICICI Bank Ltd(Bank) | ₹20.25 Cr | 04 Jul 2022 | Satisfied |
Charge IDs, lenders & amounts for Indus Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — | ||||
| 2016-17 | — | ||||
| 2015-16 | — | ||||
| 2014-15 | — |
Detailed Financials
4 FYs| Line item | 2023-24 | 2022-23 | 2021-22 | 2020-21 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | +0.0% | -76.0% | -2.0% | |
| Profit after Tax2023-24 | -80.0% | — | -69.0% | |
| Net Worth2023-24 | +1.0% | +99.0% | +48.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2014-15 | +37.51% | — | +34.49% | +29.95% | — | |||
| 2015-16 | +16.86% | -56.35% | +6.81% | +6.42% | — | |||
| 2016-17 | +39.59% | +97.67% | +27.17% | +25.00% | — | |||
| 2017-18 | +12.58% | +37.92% | +33.57% | +8.66% | 2.88 | |||
| 2018-19 | +98.34% | -29.96% | +70.93% | +40.74% | 0.74 | |||
| 2019-20 | +40.00% | +33.34% | +27.79% | +16.93% | 0.64 | |||
| 2020-21 | -100.38% | -4.25% | -200.65% | -37.63% | 4.33 | |||
| 2021-22 | +28.68% | -0.43% | +15.47% | +14.15% | 0.09 | |||
| 2022-23 | +18.78% | -26.42% | +7.02% | +6.46% | 0.09 | |||
| 2023-24 | +11.80% | -0.95% | +4.14% | +3.78% | 0.09 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 94,32,531 | 88.39% |
| Institutional Investors | 3 | 2,16,557 | 2.03% |
| Public & Others | 45 | 10,22,532 | 9.58% |
Promoter, institutional & public holding for Indus Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
8 peersTop 10 in Chemical substances used in the manufacture of anti-biotic, manufacturing
by healthView all ›Events & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.